Defense- βAny changes in political, trade, regulatory, geopolitical and economic conditions, including U.S. trade policies or the recent United States and Israeli military action in Iran and effects thereof, could have a material adverse effect on our financial condition or results of operations.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
Export controls- βWe are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
- βAmong other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which we collectively refer to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
Government customers- βRegulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public perceptions of risk, and political forces. Because clinical trials often take years to complete, it is sometimes possible for standards that exist during the conception and initiation of a clinical trial to change before the clinical trial is completed or reviewed by government regulators.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
- βChanges in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns, or changes in policy could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
- βIn addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
- βWe are unable to predict the extent to which the current U.S. government may impose or seek to impose leadership or policy changes at the U.S. federal regulatory agencies responsible for regulating our business or changes to rules and policies impacting our operations. It is unclear how these executive actions or other potential actions by the current administration or other parts of the federal government will impact the FDA or other regulatory authorities that oversee our business.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
AI regulation- βA growing number of legislators and regulators globally are adopting laws and regulations, and focusing enforcement efforts, on the development and deployment of AI. These developments may increase our compliance burden and costs and expose us to legal liability if we fail to meet evolving legal standards or if our use of such technologies results in unanticipated harms.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
Revenue, in its own words- βWe would cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the previous three years; or (iv) the date on which we are deemed to be a "large accelerated filer", which would occur if the aggregate market value of our equity securities held by non-affiliates exceeds $700.0 million as of the last business day of our most recently completed second fiscal quβ¦βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
- βWe are also a "smaller reporting company," meaning that the market value of our shares held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0 million and our annual revenue was less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i) the market value of our shares held by non-affiliates is less than $250.0 million or (ii) our annual revenue was less than $100.0 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700.0 million.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
- βWe will remain an emerging growth company until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the closing of this offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior June 30th, and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.βGeoffrey McDonough, M.D. President and Chief Executive Officer 265 Franklin Street, Suite 1702 Boston, MA 02110 (617) 694-2481
- βWe will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of the completion of this initial public offering, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which we are deemed to be a "large accelerated filer" as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of the common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, or (iv) the date on which we have issued more than $1.0 billion in non-convertible deβ¦β
Quoted from the company's own filing. Read the S-1/A at the SEC